Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Selective targeting of BCL-2 with the BH3-mimetic venetoclax has been a transformative treatment for patients with various leukemias. TP-53 controls apoptosis upstream of where BCL-2 and its prosurvival relatives, such as MCL-1, act. Therefore, targeting these prosurvival proteins could trigger apop...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Thijssen, Rachel, Diepstraten, Sarah T., Moujalled, Donia, Chew, Edward, Flensburg, Christoffer, Shi, Melissa X., Dengler, Michael A., Litalien, Veronique, MacRaild, Sarah, Chen, Maoshan, Anstee, Natasha S., Reljić, Boris, Gabriel, Sarah S., Djajawi, Tirta M., Riffkin, Chris D., Aubrey, Brandon J., Chang, Catherine, Tai, Lin, Xu, Zhen, Morley, Thomas, Pomilio, Giovanna, Bruedigam, Claudia, Kallies, Axel, Stroud, David A., Bajel, Ashish, Kluck, Ruth M., Lane, Steven W., Schoumacher, Marie, Banquet, Sébastien, Majewski, Ian J., Strasser, Andreas, Roberts, Andrew W., Huang, David C. S., Brown, Fiona C., Kelly, Gemma L., Wei, Andrew H.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2021
Matèries:
Plenary Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8138548/
https://ncbi.nlm.nih.gov/pubmed/33824975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020010167
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars